Delivery Order SPE2DB22D2108-SPE2DB25FU5UV
- Not listed
- The Defense Logistics Agency awarded a $25,044.82 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units). This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate headquarters...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Myrbetriq ER 25 mg tablets (30-count units) valued at $1,549.42. This is a firm fixed price delivery order with no set-aside designation, representing a competitive award to the pharmaceutical distributor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 4, 2025. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units) valued at $4,037.23. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The contract is scheduled for completion by August 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count units) valued at $10,076.28. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is scheduled for completion by August 13, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order through its corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count) with a ceiling value of $5,755.12. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of August 22, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Myrbetriq ER 50 mg tablets in a 90-count configuration, with a ceiling value of $6,187.69. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The order is scheduled for ultimate completion by August 19, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Myrbetriq ER 50 mg tablets (30-count units) valued at $24,075.13. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. The order is due for completion by August 14, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 3, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units) at a ceiling value of $1,761.65. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of June 4, 2025. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count units) with a ceiling value of $45,927.43. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The contract is set to be completed by September 16, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. This delivery order is a...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Myrbetriq ER 25 mg tablets in quantities of 90 units, with a ceiling value of $73,050.62. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of September 16, 2025....
- SPE2DB22D2108Indefinite Delivery Contract
- SPE2DB22D2108-SPE2DB25FU5UVDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count units) with a contract ceiling value of $16,366.65. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award through open competition. The order is due for completion by September 15, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency. The company's extensive contract portfolio with DLA demonstrates its capability to supply a comprehensive range of pharmaceutical products across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, vaccines, and medical supplies. The Myrbetriq order falls within this broader pharmaceutical support mission, providing medications to support Defense Health Agency and other federal healthcare customers. AmerisourceBergen's strategic position as a pharmaceutical prime vendor reflects its continued role in supporting global military healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.4k | 9/12/25 |